IP Library Granted Patent US 6,905,692
Granted Patent B2
US 6,905,692 · App. 10/184,665 · Granted Jun 14, 2005

Topical compositions containing probiotic bacillus bacteria, spores, and extracellular products and uses thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,905,692
App. No.
10/184,665
Granted
Jun 14, 2005
Kind
B2
Abstract

The present invention discloses compositions derived from an isolated Bacillus species, spores, or an extracellular product of Bacillus coagulans comprising a supernatant or filtrate of a culture of said Bacillus coagulans strain, suitable for topical application to the skin or mucosal membranes of a mammal, which are utilized to inhibit the growth of bacterium, yeast, fungi, virus, and combinations thereof. The present invention also discloses methods of treatment and therapeutic systems for inhibiting the growth of bacterium, yeast, fungi, virus, and combinations thereof, by topical application of therapeutic compositions which are comprised, in part, of isolated Bacillus species, spores, or an extracellular product of Bacillus coagulans comprising a supernatant or filtrate of a culture of said Bacillus coagulans strain. In addition, the present invention also discloses compositions, methods of treatment, and therapeutic systems for inhibiting the growth of bacterium, yeast, fungi, virus, and combinations thereof, comprising an extracellular product of Pseudomonas lindbergii comprising a supernatant or filtrate of a culture of said Pseudomonas lindbergii strain.

Claims (11)

1. A method of inhibiting growth of bacteria, yeast, fungus, or a virus, comprising applying to skin or a mucous membrane a composition comprising an extracellular product of a Pseudomonas lindbergii strain and an extracellular product of a Bacillus strain, wherein said Bacillus strain is selected from the group consisting of Bacillus coagulans and Bacillus coagulans hammer, and wherein growth of bacteria, yeast, fungus, or virus is inhibited by the presence of said composition.

2. The method of claim 1 , wherein said composition is in the form of an emulsion, cream, lotion, gel, oil, ointment, aerosol spray, or semi-solid formulation.

3. The method of claim 1 , wherein said composition further comprises about 1-99% Emu Oil by weight.

4. The method of claim 1 , wherein said extracellular product of a Pseudomonas lindbergii strain is a culture supernatant or a filtrate.

5. The method of claim 1 , wherein said extracellular product of a Bacillus strain is a culture supernatant or a filtrate.

6. The method of claim 1 , wherein said extracellular product of a Pseudomonas lindbergii strain and said extracellular product of a Bacillus strain are culture supernatants or filtrates.

7. A method of preventing bacterial, yeast, fungal or viral infection comprising applying to skin or a mucous membrane of a mammal a composition comprising an extracellular product of a Pseudomonas lindbergii strain and an extracellular product of a Bacillus strain, wherein said Bacillus strain is selected from the group consisting of Bacillus coagulans and Bacillus coagulans hammer, wherein said composition is in the form of an emulsion, cream, lotion, gel, oil, ointment, semi-solid formulation, or aerosol spray.

8. The method of claim 7 , wherein said extracellular product of a Pseudomonas lindbergii strain and said extracellular product of a Bacillus strain are culture supernatants or filtrates.

9. A method of preventing bacterial, yeast, fungal or viral infection comprising applying to skin or a mucous membrane of a mammal a composition comprising an extracellular product of a Pseudomonas lindbergii strain and an extracellular product of a Bacillus strain, wherein said Bacillus strain is selected from the group consisting of Bacillus coagulans and Bacillus coagulans hammer, wherein said composition prevents growth of a dermal pathogen on skin or a mucous membrane of a mammal and wherein said composition is in the form of an emulsion, cream, lotion, gel, oil, ointment, semi-solid roll-on stick, or aerosol spray.

10. The method of claim 9 , wherein said dermal pathogen is a bacteria, yeast, fungus, or virus.

11. The method of claim 9 , wherein said extracellular product of a Pseudomonas lindbergii strain and said extracellular product of a Bacillus strain are culture supernatants or filtrates.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Sep 12, 2017
From: SILICON VALLEY BANK
To: GANEDEN BIOTECH, INC.
Reel/Frame 043822/0897 →
SECURITY AGREEMENT Recorded Oct 10, 2012
From: GANEDEN BIOTECH, INC.
To: SILICON VALLEY BANK
Reel/Frame 029103/0069 →
RELEASE OF SECURITY INTEREST Recorded Dec 6, 2007
From: MIDCAP CREDIT, LLC
To: GANEDEN BIOTECH, INC.
Reel/Frame 020196/0851 →
SECURITY INTEREST Recorded Dec 23, 2005
From: GANEDEN BIOTECH, INC.
To: MIDCAP CREDIT, LLC
Reel/Frame 017136/0820 →